http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2846776-T3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd4d627b1897d87e224c3c338e44a186 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
filingDate | 2015-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6e504692ef93d14e61dbcc4f4cd4ba2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_629ae19617b37766e0247df6cbf3ab44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2eb824da710e9e91867d1ce04fab913 |
publicationDate | 2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | ES-2846776-T3 |
titleOfInvention | Site-specific dosage of a BTK inhibitor |
abstract | A solid oral dosage form, which is typically a tablet or capsule, comprising: A) a core material comprising (Z) isomer, or a mixture of (E) and (Z) isomers of (R) -2. [ 3- [4-amino-3-2-fluoro-4-phenoxy-phenyl) pyrazolo [3,4-d] pyrimidin-1-yl] piperidin-1'carbonyl] -4- [4- (oxetan-3- yl) pent-2-enenitrile, (S) -2- [3- [4-amino-3-2-fluoro-4-phenoxy-phenyl) pyrazolo [3,4-d] pyrimidine-1-carbonyl-4- methyl-4- (oxetan-3-yl) piperazin-1-yl] pent-2-enenitrile, or a mixture of (R) and (S) isomers of 2- [3- [4-amino-3-2- fluoro-4-phenoxy-phenyl) pyrazolo [3,4-d] pyrimidin-1-yl] piperidine-1-carbonyl] -4-methyl-4- [4- (oxetan-3-yl) pipera <in-1 -il] pent-2-enenitrile (Compoundv (1)) having the structure: ** (See formula) ** where * C is a stereochemical center: and / or a pharmaceutically acceptable salt thereof; (B) an enteric coating; (C) a subcoat under the enteric coating, wherein the subcoat: (1) is a hydrophilic or water soluble erodible polymer, said polymer being a low molecular weight polymer selected from hydroxymethyl cellulose (HPMC), hydroxyethyl cellulose, hydroxypropyl cellulose, microcrystalline cell , polyvinylpyrrolidones, polysaccharides, a polysaccharide derivative, polyvinyl alcohols, polyethylene glycol (PEG). polypropylene glycol (PPG), and a PEG-PPG block copolymer; or (2) comprises a water-insoluble composition comprising: (i) particles of a water-soluble compound that can form channels in the water-insoluble composition: or (ii) water-insoluble hydrophilic particles that cause swelling of the subcoat when in contact with an aqueous medium; and (D) a pharmaceutically acceptable excipient, wherein the solid oral dosage form has an onset of release of Compound (i) and / or the pharmaceutically acceptable salt thereof in the jejuno-ileal portion of the intestine of a mammal after administration; and wherein the solid oral dosage form releases at least 80% of Compound (i) and / or the pharmaceutically acceptable salt thereof in 120 minutes in a dissolution vessel comprising an aqueous solution at a pH of 6.4 to 7, Four. |
priorityDate | 2014-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1411.